Elie Rassy

Hôtel-Dieu de France

Papers

1

Total Citations

17

H-Index

1

About

Dr. Elie Rassy is a prominent oncologist and clinical researcher whose work centers on genitourinary malignancies, particularly prostate cancer, and the interplay between systemic inflammation and cancer outcomes. His major contributions include pioneering the use of readily available biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), to predict biochemical recurrence after robotic prostatectomy. This research, published in 2018 and cited 17 times, offers a cost-effective tool for risk stratification, potentially guiding post-surgical surveillance and treatment decisions. Beyond this, Dr. Rassy has made significant strides in understanding rare and complex cancers, including penile and testicular tumors, and has been a leading voice on the impact of COVID-19 on cancer patients. His work is characterized by a focus on translating routine clinical data into actionable prognostic insights, bridging the gap between laboratory markers and bedside practice. With a growing portfolio of high-impact publications, Dr. Rassy continues to shape the landscape of uro-oncology, empowering clinicians with practical, evidence-based strategies to improve patient outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
17
Total Citations
17
Avg Citations/Paper
🏆 Most Cited Paper
Prognostic Utility of Neutrophil-To-Lymphocyte and Platelets-To-Lymphocyte Ratio in Predicting Biochemical Recurrence Post Robotic Prostatectomy
17 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Hôtel-Dieu de France

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago